Monday, 20 May 2019

You are here

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change. At EULAR 2018 a study of 1776 patients from the VA database showed again the notion that if a patient is in high disease activity, treatment changes are made only half the time (FRI0018). My response to this is that the measures are not reflecting active RA (i.e. scores driven by non-inflammatory pain, tender joints from OA), or the patient refuses to accept more treatment or the most likely is that the score is not being calculated (i.e. for billing reimbursement, the components are collected but scores are not calculated during the visit) as the physician doesn’t think the disease is active (enough) to warrant a treatment change. However, even more strangely, 15% who were in remission had dose increasing or a new drug started and 21 to 25% in low disease activity had increases in treatment. I can say that the disease activity instruments used in the study (DAS28, CDAI and RAPID3) had a ‘dose response’ meaning that the frequency of treatment increases was lowest in remission, and highest in high disease activity and there will never be 100% concordance with outcome measures and treatment changes in clinical practice. It is too bad we don’t have the HbA1C (glycated Hbg) equivalent of RA – one easy test reflecting recent disease activity that we could target.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.

Denosumab Protects Against RA Erosions

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

New ACR/AF Guidelines on JIA Polyarthritis and Uveitis

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA). The first addresses the treatement of non-systemic polyarthritis, sacroilitis and enthesitis; and the second focuses on JIA associated uveitis - screening, monitoring and treatment.

Shorter Treatment Succeeds in Septic Arthritis

Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.

Among 77 patients randomized to a 4-week course of therapy following surgical drainage for native joint bacterial arthritis, the rate of complete microbiological remission after at least 2 months of follow-up was 97%, according to Ilker Uçkay, MD, of Uniklinik Balgrist in Zurich, Switzerland, and colleagues.

Targeting GM-CSF Works in Rheumatoid Arthritis

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.